Brain : a journal of neurology
GFAP and NfL as predictors of disease progression and relapse activity in fingolimod-treated multiple sclerosis.
Aleksandra Maleska Maceski, Pascal Benkert, Maximilian Einsiedler, Sabine Schaedelin, Johanna Oechtering, Lester Melie-Garcia, Alessandro Cagol, Riccardo Galbusera, Edoardo Galli, Jannis Mueller, Sebastian Finkener, Patrice H Lalive, Marjolaine Uginet, Stefanie Müller, Caroline Pot
Published: 202510.1093/brain/awaf433
Abstract
In multiple sclerosis (MS) patients under therapy, the increase of serum glial fibrillary acidic protein (sGFAP) concentrations is associated with the course of 'progression in absence of relapse' (PIRA). While serum neurofilament light chain (sNfL)…
Preview only. Read the full abstract at the source